{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:32:17Z","timestamp":1761060737728,"version":"3.37.3"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T00:00:00Z","timestamp":1547769600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Health management and economics research center, Iran University of Medical Sciences","award":["95-02-163-28619"],"award-info":[{"award-number":["95-02-163-28619"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s11096-018-00778-z","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T18:10:21Z","timestamp":1547835021000},"page":"22-29","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative efficacy of ivabradine versus beta-blockers in patients with mitral stenosis in sinus rhythm: systematic review and meta-analysis"],"prefix":"10.1007","volume":"41","author":[{"given":"Nashmil","family":"Ghadimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Kaveh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Shabaninejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alaadine","family":"Lijassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Zahed","family":"Mehr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1308-1244","authenticated-orcid":false,"given":"Hossein","family":"Hosseinifard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,18]]},"reference":[{"issue":"3","key":"778_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00392-012-0516-3","volume":"102","author":"V Santis De","year":"2013","unstructured":"De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171\u20138.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"778_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-012-9347-6","volume":"18","author":"M Guglin","year":"2013","unstructured":"Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517\u201328.","journal-title":"Heart Fail Rev"},{"issue":"8484","key":"778_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0140-6736(86)91780-0","volume":"327","author":"M Al Zaibag","year":"1986","unstructured":"Al Zaibag M, Al Kasab S, Ribeiro P, Al Fagih M. Percutaneous double-balloon mitral valvotomy for rheumatic mitral-valve stenosis. Lancet. 1986;327(8484):757\u201361.","journal-title":"Lancet"},{"issue":"4","key":"778_CR4","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0146-2806(98)80005-4","volume":"23","author":"BA Carabello","year":"1998","unstructured":"Carabello BA. Mitral valve regurgitation. Curr Probl Cardiol. 1998;23(4):197\u2013241.","journal-title":"Curr Probl Cardiol"},{"key":"778_CR5","doi-asserted-by":"crossref","unstructured":"Sun JP, Felner JM. Mitral Valve Stenosis. Practical Handbook of Echocardiography: 101 Case Studies. 2010:38-41.","DOI":"10.1002\/9781444320367.ch11"},{"issue":"2","key":"778_CR6","first-page":"345","volume":"10","author":"F Muhammad","year":"2016","unstructured":"Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345\u20137.","journal-title":"Pak J Med Health Sci"},{"issue":"3","key":"778_CR7","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2006.05.021","volume":"48","author":"RO Bonow","year":"2006","unstructured":"Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr., Faxon DP, Freed MD, et al. ACC\/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. 2006;48(3):e1\u2013148.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"778_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10741-012-9347-6","volume":"18","author":"M Guglin","year":"2013","unstructured":"Guglin M. Heart rate reduction in heart failure: ivabradine or beta blockers? Heart Fail Rev. 2013;18(4):517\u201328.","journal-title":"Heart Fail Rev"},{"issue":"38","key":"778_CR9","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"TF Members","year":"2013","unstructured":"Members TF, Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, et al. ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34(38):2949\u20133003.","journal-title":"Eur Heart J"},{"issue":"14","key":"778_CR10","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2174\/0929867311320140002","volume":"20","author":"G Riccioni","year":"2013","unstructured":"Riccioni G. Ivabradine: the hope for a good treatment of ischemic heart disease. Curr Med Chem. 2013;20(14):1817\u201323.","journal-title":"Curr Med Chem"},{"issue":"5","key":"778_CR11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/000331970205300512","volume":"53","author":"S Alan","year":"2002","unstructured":"Alan S, Ulgen MS, Ozdemir K, Keles T, Toprak N. Reliability and efficacy of metoprolol and diltiazem in patients having mild to moderate mitral stenosis with sinus rhythm. Angiology. 2002;53(5):575\u201381.","journal-title":"Angiology"},{"issue":"2","key":"778_CR12","first-page":"199","volume":"11","author":"JM Monmeneu","year":"2002","unstructured":"Monmeneu JM, Mar\u00edn FO, Reyes FG, Jord\u00e1n AT, Garc\u00eda MM, Bod\u00ed VP, et al. Beta-blockade and exercise capacity in patients with mitral stenosis in sinus rhythm. J Heart Valve Dis. 2002;11(2):199\u2013203.","journal-title":"J Heart Valve Dis"},{"issue":"5","key":"778_CR13","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/eurheartj\/ehn571","volume":"30","author":"J-C Tardif","year":"2009","unstructured":"Tardif J-C, Ponikowski P, Kahan T. Efficacy of the I\n                           f current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540\u20138.","journal-title":"Eur Heart J"},{"issue":"5","key":"778_CR14","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.phrs.2006.03.006","volume":"53","author":"D DiFrancesco","year":"2006","unstructured":"DiFrancesco D. Funny channels in the control of cardiac rhythm and mode of action of selective blockers. Pharmacol Res. 2006;53(5):399\u2013406.","journal-title":"Pharmacol Res"},{"issue":"3","key":"778_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s00392-012-0516-3","volume":"102","author":"V Santis De","year":"2013","unstructured":"De Santis V, Vitale D, Santoro A, Magliocca A, Porto AG, Nencini C, et al. Ivabradine: potential clinical applications in critically ill patients. Clin Res Cardiol. 2013;102(3):171\u20138.","journal-title":"Clin Res Cardiol"},{"issue":"Spec Feature","key":"778_CR16","first-page":"56","volume":"9","author":"L Fala","year":"2016","unstructured":"Fala L. Corlanor (Ivabradine), First HCN Channel Blocker, FDA Approved for the Treatment of Patients with Heart Failure. Am Health Drug Benefits. 2016;9(Spec Feature):56.","journal-title":"Am Health Drug Benefits"},{"issue":"5","key":"778_CR17","doi-asserted-by":"publisher","first-page":"4924","DOI":"10.3390\/molecules17054924","volume":"17","author":"L Speranza","year":"2012","unstructured":"Speranza L, Franceschelli S, Riccioni G. The biological effects of ivabradine in cardiovascular disease. Molecules. 2012;17(5):4924\u201335.","journal-title":"Molecules"},{"key":"778_CR18","first-page":"47","volume":"6","author":"I Urbanek","year":"2014","unstructured":"Urbanek I, Kaczmarek K, Cygankiewicz I, Ptaszynski P. Risk-benefit assessment of ivabradine in the treatment of chronic heart failure. Drug Healthc Patient Saf. 2014;6:47.","journal-title":"Drug Healthc Patient Saf"},{"issue":"3","key":"778_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1159\/000447443","volume":"135","author":"K Werdan","year":"2016","unstructured":"Werdan K, Perings S, K\u00f6ster R, Kelm M, Meinertz T, St\u00f6ckl G, et al. Effectiveness of ivabradine treatment in different subpopulations with stable angina in clinical practice: a pooled analysis of observational studies. Cardiology. 2016;135(3):141\u201350.","journal-title":"Cardiology"},{"key":"778_CR20","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijcard.2016.07.022","volume":"221","author":"V Agrawal","year":"2016","unstructured":"Agrawal V, Kumar N, Lohiya B, Sihag BK, Prajapati R, Singh T, et al. Metoprolol vs ivabradine in patients with mitral stenosis in sinus rhythm. Int J Cardiol. 2016;221:562\u20136.","journal-title":"Int J Cardiol"},{"issue":"2","key":"778_CR21","first-page":"345","volume":"10","author":"F Muhammad","year":"2016","unstructured":"Muhammad F, Nazeer A, Rehman Z. The comparison of effects of ivabradine and atenolol on heart rate and symptoms in patients with mild-to-moderate mitral stenosis. Pak J Med Health Sci. 2016;10(2):345\u20137.","journal-title":"Pak J Med Health Sci"},{"issue":"3","key":"778_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ihj.2015.09.028","volume":"68","author":"GN Rajesh","year":"2016","unstructured":"Rajesh GN, Sajeer K, Sajeev CG, Bastian C, Vinayakumar D, Muneer K, et al. A comparative study of ivabradine and atenolol in patients with moderate mitral stenosis in sinus rhythm. Indian Heart J. 2016;68(3):311\u20135.","journal-title":"Indian Heart J"},{"issue":"6","key":"778_CR23","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1097\/FJC.0000000000000222","volume":"65","author":"DK Saggu","year":"2015","unstructured":"Saggu DK, Narain VS, Dwivedi SK, Sethi R, Chandra S, Puri A, et al. Effect of ivabradine on heart rate and duration of exercise in patients with mild-to-moderate mitral stenosis: a randomized comparison with metoprolol. J Cardiovasc Pharmacol. 2015;65(6):552.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"4","key":"778_CR24","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.cardfail.2012.01.001","volume":"18","author":"N Parakh","year":"2012","unstructured":"Parakh N, Chaturvedi V, Kurian S, Tyagi S. Effect of ivabradine vs atenolol on heart rate and effort tolerance in patients with mild to moderate mitral stenosis and normal sinus rhythm. J Card Fail. 2012;18(4):282\u20138.","journal-title":"J Card Fail"},{"issue":"7","key":"778_CR25","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"778_CR26","unstructured":"Higgins J. Green S. Cochrane handbook for systematic reviews of interventions Version 5.1. 0. The Cochrane Collaboration. Confidence intervals. 2011."},{"key":"778_CR27","unstructured":"Otto CM, Gaasch W, Yeon S. Clinical Manifestations and diagnosis of rheumatic mitral stenosis. UpToDate, Post, TW. 2018."},{"key":"778_CR28","first-page":"25","volume":"101","author":"H Mardikar","year":"1995","unstructured":"Mardikar H, Sahasrabhojaney V, Jalgaonkar P, Mahorkar U, Mardikar M, Waghmare B. Long term effects of atenolol in patients of mitral stenosis and normal sinus rhythm. Indian J Med Res. 1995;101:25\u20137.","journal-title":"Indian J Med Res"},{"issue":"3","key":"778_CR29","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000073933","volume":"100","author":"M Manz","year":"2003","unstructured":"Manz M, Reuter M, Lauck G, Omran H, Jung W. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction. Cardiology. 2003;100(3):149\u201355.","journal-title":"Cardiology"},{"issue":"Suppl 2","key":"778_CR30","first-page":"S6","volume":"11","author":"E Pasceri","year":"2009","unstructured":"Pasceri E, Curcio A, Achille F, de Serio D, Zinzi S, Torella D. Acute reduction of transmitral gradient after I (f) channel inhibition in patients with mitral valve stenosis or a mitral annuloplasty ring [Abst 974]. Europace. 2009;11(Suppl 2):S6.","journal-title":"Europace"},{"issue":"6","key":"778_CR31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS, Fox K, Jaillon P, Lerebours G. Antianginal and antiischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817\u201323.","journal-title":"Circulation"},{"issue":"4","key":"778_CR32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1159\/000108387","volume":"108","author":"L L\u00f3pez-Besc\u00f3s","year":"2007","unstructured":"L\u00f3pez-Besc\u00f3s L, Filipova S, Martos R. Long-term safety and efficacy of ivabradine in patients with chronic stable angina. Cardiology. 2007;108(4):387\u201396.","journal-title":"Cardiology"},{"issue":"23","key":"778_CR33","doi-asserted-by":"publisher","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"J-C Tardif","year":"2005","unstructured":"Tardif J-C, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective I\n                           f inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529\u201336.","journal-title":"Eur Heart J"},{"key":"778_CR34","doi-asserted-by":"crossref","unstructured":"Ye L, Ke D, Chen Q, Li G, Deng W, Wu Z. Effectiveness of ivabradine in treating stable angina pectoris. Medicine. 2016;95(14):e3245.","DOI":"10.1097\/MD.0000000000003245"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-018-00778-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-00778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-018-00778-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,17]],"date-time":"2020-01-17T19:09:24Z","timestamp":1579288164000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-018-00778-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,18]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["778"],"URL":"https:\/\/doi.org\/10.1007\/s11096-018-00778-z","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2019,1,18]]},"assertion":[{"value":"9 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}